Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?

References

• Marin JJG, Prete MG, Lamarca A, et al. Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer. 2020;123(7):1047–1059.
   PubMed Web of Science ®Google Scholar
• Altekruse SF, Petrick JL, Rolin AI, et al. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS One. 2015;10(3):e0120574.
   PubMed Web of Science ®Google Scholar
• Saha SK, Zhu AX, Fuchs CS, et al. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: intrahepatic Disease on the Rise. Oncologist. 2016;21(5):594–599.
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104–114.
   PubMed Web of Science ®Google Scholar
• Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136(4):1134–1144.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2017. Bethesda, MD: National Cancer Institute; 2020 April. https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site. Last accessed November 20, 2020.
   Google Scholar
• El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic Cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28(4):587–599.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–1289.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Rodríguez De Lope C, Gastaca M, et al. “Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? Am J Transplant. 2014;14(3):660–667.
   PubMed Web of Science ®Google Scholar
• Sapisochin G, Facciuto M, Rubbia-Brandt L, et al. Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology. 2016;64(4):1178–1188.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Ross P, Wasan HS, et al. Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, −02, and −03 Clinical Trials. J Natl Cancer Inst. 2020;112(2):200–210.
   PubMedGoogle Scholar
• Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–474.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. [abstract ABC-06]. J Clin Oncol. 2019;37(5_suppl. 15):4003
   Google Scholar
• Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–1473.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087. Published 2015 Jan 22.
   PubMed Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014;19(3):235–242.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Kapacee Z, Breeze M, et al. molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers. J Clin Med. 2020;9(9):2854.
   Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• TCGA Research Network. Genomic Data Commons Data Portal. [cited 2020 Nov 23]. Available from: https://portal.gdc.cancer.gov/exploration?facetTab=clinical&filters=%7B%22op%22%3A%22and%22%2C%22content%22%3A%5B%7B%22op%22%3A%22in%22%2C%22content%22%3A%7B%22field%22%3A%22cases.diagnoses.primary_diagnosis%22%2C%22value%22%3A%5B%22cholangiocarcinoma%22%5D%7D%7D%2C%7B%22op%22%3A%22in%22%2C%22content%22%3A%7B%22field%22%3A%22cases.project.project_id%22%2C%22value%22%3A%5B%22TCGA-CHOL%22%5D%7D%7D%2C%7B%22op%22%3A%22in%22%2C%22content%22%3A%7B%22field%22%3A%22genes.is_cancer_gene_census%22%2C%22value%22%3A%5B%22true%22%5D%7D%7D%5D%7D&searchTableTab=genes.
   Google Scholar
• Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014;9(12):e115383.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21(12):3827–3834.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–4161.
   PubMed Web of Science ®Google Scholar
• Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013 Jun 20;32(25):3091–3100.
   PubMed Web of Science ®Google Scholar
• Saha SK, Parachoniak CA, Ghanta KS, et al. Corrigendum: mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature. 2015 Dec 3;528(7580):152.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Kommalapati A, Tella SH, et al. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs. 2018;27(9):709–720.
   PubMed Web of Science ®Google Scholar
• Masclef L, Ahmed O, Estavoyer B, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ. 2021;28(2):606–625
   PubMed Web of Science ®Google Scholar
• Kongpetch S, Jusakul A, Ong CK, et al. Pathogenesis of cholangiocarcinoma: from genetics to signalling pathways. Best Pract Res Clin Gastroenterol. 2015;29(2):233–244.
   PubMed Web of Science ®Google Scholar
• Wu Y-M, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–647.
   PubMed Web of Science ®Google Scholar
• Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427–1434.
   PubMed Web of Science ®Google Scholar
• Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum Pathol. 2014;45(8):1630–1638.
   PubMed Web of Science ®Google Scholar
• Moeini A, Sia D, Bardeesy N, et al. Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res. 2016;22(2):291–300.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang H, Wan L, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020;73(5):1118–1130.
   PubMed Web of Science ®Google Scholar
• Wang F, Kan M, Xu J, et al. Ligand-specific structural domains in the fibroblast growth factor receptor. J Biol Chem. 1995;270(17):10222–10230.
   PubMed Web of Science ®Google Scholar
• Farrell B, Breeze AL. Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting. Biochem Soc Trans. 2018;46(6):1753–1770.
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005;16:107–137.
   PubMed Web of Science ®Google Scholar
• Kalinina J, Dutta K, Ilghari D, et al. The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition. Structure. 2012;20:77–88.
   PubMed Web of Science ®Google Scholar
• Dai S, Zhou Z, Chen Z, et al. Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells. 2019;8(6):614.
   PubMed Web of Science ®Google Scholar
• Guimarães CR, Rai BK, Munchhof MJ, et al. Understanding the impact of the P-loop conformation on kinase selectivity. J Chem Inf Model. 2011;51(6):1199–1204.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134.
   PubMed Web of Science ®Google Scholar
• Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34(2):280–300.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4(3):215–266.
   PubMed Web of Science ®Google Scholar
• Chen H, Marsiglia WM, Cho MK, et al. Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases. Elife. 2017;6:e21137. Published 2017 Feb 6
   Google Scholar
• Katoh M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. 2019;16(2):105–122.
   PubMed Web of Science ®Google Scholar
• Farshidfar F, Zheng S, Gingras MC, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles [published correction appears in cell rep. 2017 Jun 27;19(13):2878-2880]. Cell Rep. 2017;18(11):2780–2794.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of bgj398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282.
   PubMed Web of Science ®Google Scholar
• Shin E, Lim DH, Han J, et al. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. BMC Ophthalmol. 2020;20:19.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684.
   Google Scholar
• Silverman IM, Hollebecque A, Friboulet L, et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 2021;11(2):326–339.
   PubMed Web of Science ®Google Scholar
• Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7:252–263.
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9:1064–1079.
   PubMed Web of Science ®Google Scholar
• Krook MA, Bonneville R, Chen HZ, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019;5:a004002.
   PubMed Web of Science ®Google Scholar
• Chen H, Ma J, Li W, et al. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell. 2007;27:717–730.
   PubMed Web of Science ®Google Scholar
• Huang Z, Chen H, Blais S, et al. Structural mimicry of a-loop tyrosine phosphorylation by a pathogenic FGF receptor 3 mutation. Structure. 2013;21:1889–1896.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Center for Drug Evaluation and Research. “FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion.” U.S. FDA, 17 April 2020. [cited 2020 Nov 21]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion
   Google Scholar
• Goyal L, Meric-Bernstam F, Hollebecque A, et al. FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. J Clin Oncol. 2020;38(5_suppl. 15):108.
   Web of Science ®Google Scholar
• Furuse J, Goyal L, Meric-Bernstam F, et al. Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2. Ann Oncol. 2020;31(suppl_6):S1287–S1318.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–171.
   PubMed Web of Science ®Google Scholar
• Park JO, Feng Y, Chen Y, et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J Clin Oncol. 2019;37(5_suppl. 15):4117.
   Web of Science ®Google Scholar
• Bahleda R, Italiano A, Hierro C, et al. Multicenter phase i study of Erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25(16):4888–4897.
   PubMed Web of Science ®Google Scholar
• Voss MH, Hierro C, Heist RS, et al. A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations. Clin Cancer Res. 2019;25:2699–2707.
   PubMed Web of Science ®Google Scholar
• Ng MCH, Goyal L, Bang YJ, et al. AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results. Hepatobiliary Surg Nutr. 2019;8(Suppl. 1):AB065.
   Google Scholar
• Wu D, Guo M, Min X, et al. LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance. Chem Commun (Camb). 2018;54:12089–12092.
   PubMed Web of Science ®Google Scholar
• Michael M, Bang YJ, Park YS, et al. A phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer. Target Oncol. 2017;12(4):463–474.
   PubMed Web of Science ®Google Scholar
• Chae YK, Hong F, Vaklavas C, et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020;38(21):2407–2417.
   PubMed Web of Science ®Google Scholar
• Saborowski A, Lehmann U, Vogel A. FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next? Ther Adv Med Oncol. 2020 Published 2020 Sep 16;12:1758835920953293.
   Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185.
   PubMed Web of Science ®Google Scholar
• Delahousse J, Verlingue L, Broutin S, et al. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas. Eur J Cancer. 2018;90:83–91.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [published correction appears in Lancet Oncol. 2020 Oct;21(10):e462]. Lancet Oncol. 2020;21(6):796–807.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Burris HA 3rd, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(9):711–720.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–363.
   PubMed Web of Science ®Google Scholar
• Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 2017;36(1):141–157.
   PubMed Web of Science ®Google Scholar
• Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58. Published 2015 May 29.
   PubMed Web of Science ®Google Scholar
• Harding J, Cleary J, Shapiro G, et al. O-005—treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial. Ann Oncol. 2019;30:iv127.
   Web of Science ®Google Scholar
• Chun YS, Javle M. Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729241.
   Web of Science ®Google Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. The Lancet Oncology. 2020;21(9):1234–1243.
   PubMed Web of Science ®Google Scholar
• Personeni N, Lleo A, Pressiani T, et al. Biliary tract cancers: molecular heterogeneity and new treatment options. Cancers (Basel). 2020;12(11):3370.
   Web of Science ®Google Scholar
• Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–962.
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023.
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Colombo M. Systemic therapy for advanced cholangiocarcinoma: new options on the horizon. Hepatoma Res. 2020;6. DOI:10.20517/2394-5079.2020.65.
   Google Scholar
• U.S. Food and Drug Administration. Center for Drug Evaluation and Research“FDA approves larotrectinib for solid tumors with NTRK gene fusions.” U.S. FDA, 14 December 2018. [cited 2020 Feb 3]. Available from: https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0
   Google Scholar
• U.S. Food and Drug Administration. Center for Drug Evaluation and Research. “FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC” U.S. FDA, 16 August 2019. [cited 2021 Feb 3]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc.
   Google Scholar
• Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin. Clin. Oncol. 2016;5(62):62.
   PubMedGoogle Scholar
• Fontugne J, Augustin J, Pujals A, et al. PD- L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget. 2017;8(15):24644–24651.
   PubMedGoogle Scholar
• Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint nd tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann. Surg. Oncol. 2016;23(8):2610–2617.
   PubMed Web of Science ®Google Scholar
• Ueno M, Chung HC, Nagrial A, et al. Pembrolizumab for advanced biliary adenocarcinoma: results from the multicohort, phase 2 KEYNOTE-158 study. Ann. Oncol. 2018;29(Suppl. 8):viii205–viii270.
   Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials [published correction appears in Lancet Oncol. 2020 Feb;21(2):e70][published correction appears in Lancet Oncol. 2020 Jul;21(7):e341][published correction appears in Lancet Oncol. 2020 Aug;21(8):e372]. Lancet Oncol. 2020;21(2):271–282.
   PubMed Web of Science ®Google Scholar
• Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888–894.
   PubMed Web of Science ®Google Scholar
• Bang Y-J, Ueno M, Malka D, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.. J Clin Oncol. 2019;5(5):4079.
   Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1–10.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–1365.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–931.
   PubMed Web of Science ®Google Scholar
• Roger A, Finet A, Boru B, et al. Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. Oncoimmunology. 2018;7(7):e1442166.
   PubMed Web of Science ®Google Scholar
• Rodolfo C-S, Ignacio M-O, Juan C-M, et al. Stereotactic ablative radiotherapy combined with immune checkpoint inhibitors reboots the immune response assisted by immunotherapy in metastatic lung cancer: a systematic review. Int J Mol Sci. 2019;20(9):2173.
   Web of Science ®Google Scholar
• Fiorica F, Belluomini L, Stefanelli A, et al. Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination. Am J Clin Oncol. 2018;41(11):1101–1105.
   PubMed Web of Science ®Google Scholar
• Sharabi A, Kim SS, Kato S, et al. Exceptional response to Nivolumab and stereotactic body radiation therapy (SBRT) in neuroendocrine cervical carcinoma with high tumor mutational burden: management considerations from the center for personalized Cancer therapy at UC san Diego Moores Cancer center. Oncologist. 2017;22:631–637.
   PubMed Web of Science ®Google Scholar
• Qin Q, Nan X, Miller T, et al. Complete local and Abscopal responses from a combination of radiation and Nivolumab in refractory Hodgkin’s lymphoma. Radiat Res. 2018;190:322–329.
   PubMed Web of Science ®Google Scholar
• Liu X, Yao J, Song L, et al. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer. 2019;7(1):204.
   PubMed Web of Science ®Google Scholar
• Liu ZL, Liu X, Peng H, et al. Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: a Case Report. Front Med (Lausanne). 2020;7:368. Published 2020 Aug 28.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–830.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Tella SH, Kommalapati A, et al. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol. 2020;155:103091.
   PubMed Web of Science ®Google Scholar
• Tella SH, Kommalapati A, Borad MJ, et al. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020;21(1):e29–e41.
   PubMed Web of Science ®Google Scholar